Entera Bio Ltd

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entera Bio (ENTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Entera Bio (ENTX) is Overbought: Is A Drop Coming?

‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒

Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis

Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year

BioNTech SE

Ocugen, Inc.

Rubius Therapeutics Inc

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

4 Biotech Stocks That Have Already Doubled This Year So Far

BOSTON and JERUSALEM, April 20, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat of Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010, and was Chairman from 2014 to 2016.

Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

BOSTON and JERUSALEM, Israel, April 15, 2021 (GLOBE NEWSWIRE) --  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Entera's interim U.S. CFO.

Entera Appoints Ramesh Ratan as Chief Financial Officer

BOSTON and JERUSALEM, April 06, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled “Pharmacokinetics of an Oral Human Growth Hormone (hGH) Formulation in Rats and Mice” at the 31st Annual European Pharma Congress in London on April 28-29, 2021.

New Data Suggest Entera's Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress

Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2020 Results - Earnings Call Transcript

‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data , Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approv al of EB613 IND for the Treatment of O steoporosis Enables Initial U.S. Clinical Trial ‒ ‒ Amgen Collaboration Continues to Progress ; Company Evaluating Additional Molecules, Including GLP-2, in Multiple  Pre-clinical Studies ‒ ‒ Company Strengthened Balance Sheet and Now Funded i nto the Second Quarter of 2022 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒

Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

The stock price of Entera Bio Ltd (NASDAQ: ENTX) increased by 70.79% yesterday. This is why it happened.

ENTX Stock Price Increased 70.79%: Why It Happened

ENTX stock continues to sky rocket, leading investors to question halted stocks. Here's what you should know now.

Halted Stocks: What to Know as ENTX Stock Faces Trading Halts

Entera Bio Ltd (NASDAQ: ENTX) shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint. According to Entera, EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis patients.

Why Entera Bio's Stock Is Surging Higher Today

The stock price of Entera Bio Ltd (Nasdaq: ENTX) has increased by over 40% pre-market. This is why it happened.

ENTX Stock Price Increases Over 40% Pre-Market: Why It Happened

BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020 on March 18, 2021, before the U.S. financial markets open.

Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021

Entera Bio (ENTX) stock is soaring higher on Thursday following an update from the biotech company about its osteoporosis treatment. The post ENTX Stock: 11 Things for Entera Bio Investors to Know as Shares Blast 200%+ Higher appeared first on InvestorPlace.

ENTX Stock: 11 Things for Entera Bio Investors to Know as Shares Blast 200%+ Higher

Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral density). Three-month bone biomarker data analysis showed a significant increase in the P1NP biomarker in the 2.5 mg dose group after three months of treatment compared to placebo.

Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study

The stock price of Entera Bio Ltd. (NASDAQ: ENTX) has increased by over 200% pre-market.

ENTX Stock Price Increases Over 200% Pre-Market: Why It Happened

‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2:21 ‒

Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data

BOSTON and JERUSALEM, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.

Entera Bio Issues Letter to Shareholders

EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21 EB613 Phase 2 Placebo-Controlled, Dose-Ranging Study Ongoing in Israel with Complete 3 Month Biomarker Data expected in Q1:21 and Final Bone Mineral Density, or BMD, Data Expected in Q2:21

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript

‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density ( BMD ) Data Reported in Phase 2 EB613 Clinical Trial ‒ ‒ Company Expect s to Report Bio m arker Data that Includes the 2.5 mg Dose in Q1:21 and Final Data from The Phase 2 Trial Including BMD in Q2: 21 ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ‒

Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update

BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on November 19, 2020, before the U.S. financial markets open.

Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020

‒ Company Expect s to Report Interim 3 Month Bio m arker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

BOSTON and JERUSALEM, Sept.  10, 2020  (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference on Tuesday, September 15, 2020 at 3:00 p.m. EDT.

News for Entera Bio Ltd Stock (ENTX)